As retinal vascular abnormalities are prevalent comorbidities of DR, and GLP-1R analogs have already been used clinically in diabetes and obesity, further pre- and clinical research is necessary to elucidate the regulative mechanism underlying GLP-1R/SGLT2 signaling in DR. This evidence concerns the gene GLP1R and obesity disorder.